REGN Add to watchlist $753.93 1.58 (-0.21%) Last updated: Apr 16, 2026 00:58
52-Week Range
$753.93
$476.49 $753.93 $821.11

Fundamentals Overview

Regeneron Pharmaceuticals, Inc. is near the high of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/E 18 PEG 8.6 P/B 2.48 P/S 5.46

Intrinsic value (DCF)

+173.3% upside vs price

Profitability

Net margin 31.4%

Risk (Beta)

0.4 — lower vol

Earnings & growth

EPS $41.91 Rev +3.5% Profit -42.2% vs prior qtr

BullzEye Analysis

Our composite tilts Buy on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Buy — 68% confidence Risk: Lower Volatility — Beta 0.4. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +173.3% upside vs price · Analyst grade: A

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$78.34B
P/E (TTM)
17.99
EPS (TTM)
$41.91
Dividend Yield
0.24%
52-Week Range
$476.49 - $821.11
Volume vs Avg
N/A
Beta
0.4

About

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vei...
Sector: Healthcare
Headquarters: US
Employees: 15,158
IPO Date: Apr 1991
Beta: 0.4 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: A. Recent institutional grades: mixed. Current institutional positions: Buy: 10, Equal Weight: 8, Neutral: 1, Outperform: 4, Overweight: 3, Sector Perform: 3, Underperform: 1.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $2,060.21; current price is $753.93. That’s a +173.3% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 17.99
DCF value (model) $2,060.21 (173.3% upside)
PEG (TTM) 8.6
P/B (TTM) 2.48
P/S (TTM) 5.46
P/FCF (TTM) 19.2
Liquidity & enterprise
Current Ratio (TTM) 4.13
Quick Ratio (TTM) 3.39
Cash Ratio (TTM) 0.71
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 31.41%
Gross margin (TTM) 85.35%
Operating margin (TTM) 24.95%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for REGN.

Analyst Sentiment at a Glance

A Sentiment Mixed
Buy 10Equal Weight 8Neutral 1Outperform 4Overweight 3Sector Perform 3Underperform 1
1 upgrade, 1 downgrade
Price Target Consensus
Current $753.93
Median $870.00
Consensus $864.42
Low consensus $700.00
High consensus $1,057.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Morgan Stanley maintain Equal Weight Equal Weight 2026-04-10
Bernstein maintain Outperform Outperform 2026-04-08
Truist Securities maintain Buy Buy 2026-03-31
RBC Capital maintain Sector Perform Sector Perform 2026-03-02
Guggenheim maintain Buy Buy 2026-02-09
Wells Fargo maintain Equal Weight Equal Weight 2026-02-02
Truist Securities maintain Buy Buy 2026-02-02
Oppenheimer maintain Outperform Outperform 2026-02-02
Morgan Stanley maintain Equal Weight Equal Weight 2026-02-02
Cantor Fitzgerald maintain Overweight Overweight 2026-02-02
JP Morgan maintain Overweight Overweight 2026-02-02
Evercore ISI Group maintain Outperform Outperform 2026-01-22
Truist Securities maintain Buy Buy 2026-01-08
B of A Securities upgrade Underperform Buy 2026-01-07
Morgan Stanley maintain Equal Weight Equal Weight 2025-12-12
Wells Fargo maintain Equal Weight Equal Weight 2025-12-10
BMO Capital maintain Outperform Outperform 2025-12-04
Canaccord Genuity maintain Buy Buy 2025-12-04
Morgan Stanley downgrade Overweight Equal Weight 2025-12-03
Scotiabank maintain Sector Perform Sector Perform 2025-11-24
Wells Fargo maintain Equal Weight Equal Weight 2025-11-20
UBS maintain Neutral Neutral 2025-11-07
Citigroup maintain Buy Buy 2025-10-29
B of A Securities maintain Underperform Underperform 2025-10-29
Wells Fargo maintain Equal Weight Equal Weight 2025-10-29
Guggenheim maintain Buy Buy 2025-10-29
Cantor Fitzgerald maintain Overweight Overweight 2025-10-29
RBC Capital maintain Sector Perform Sector Perform 2025-10-29
Canaccord Genuity maintain Buy Buy 2025-10-23
Canaccord Genuity maintain Buy Buy 2025-10-14